Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma
The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs in pancreatic ductal adenocarcinoma (PDAC).
Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO).
SINGAPORE, May 28, 2025 /CNW/ -- The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for EBC-129 for the treatment of pancreatic ductal adenocarcinoma (PDAC). EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. It is currently undergoing Phase 1 clinical trials for the treatment of patients with solid tumours with high unmet medical need.
The Fast Track Designation facilitates the expedited development of EBC-129, enabling more frequent engagement with the FDA to discuss the clinical development plan. It also provides potential eligibility for Priority Review and Accelerated Approval, as well as rolling review of any future Biologic License Application (BLA).
"The FDA's Fast Track Designation for EBC-129 underscores the promise of this novel ADC in addressing the critical need for expanded treatment options for PDAC patients and represents an important step in our efforts to accelerate its development. We view this as both a validation of our efforts and a responsibility to move decisively to advance EBC-129 as a new option to patients in need," said Professor Damian O'Connell, Chief Executive Officer of EDDC.
Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from 30 May to 3 June 2025.
Presentation Details at ASCO 2025:
Title: Clinical activity of EBC-129, a first-in class, anti-N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a Phase 1 study
Rapid Oral Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Date and Time: Monday, June 2, 2025, 11:30 AM – 1:00 PM GMT-5
Abstract Number: 4018
Presenter: Assistant Professor Robert W. Lentz, MD, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine
About EBC-129
EBC-129 is an ADC that targets a tumour-specific N256-glycosylation site conserved on CEACAM5 and CEACAM6. CEACAM5 and CEACAM6 are known to have functional importance in tumour formation, migration and metastasis. In the ongoing trial, the tumour-specific marker is found to be widely expressed in multiple solid tumour types, including gastric, oesophageal, pancreatic, lung, colorectal, and appendiceal cancers, based on an analytically validated immunohistochemistry (IHC) assay. The payload used in EBC-129 is monomethyl auristatin E (MMAE) which has been extensively tested and approved for clinical use in other marketed ADCs and has demonstrated synergy with PD-1 inhibitors. The ongoing Phase 1 trial of EBC-129 is assessing the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours. Enrolment for the PDAC cohort in the Phase 1 dose expansion study is now complete, while recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts.
For information about the trial, please visit Clinicaltrial.gov, trial identifier NCT05701527.
About the Experimental Drug Development Centre
The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit www.eddc.sg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 days ago
- Cision Canada
LBB Specialties Expands Distribution Partnership with Clariant to Support Puerto Rico's Life Sciences Market
NORWALK, Conn., July 9, 2025 /CNW/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce the expansion of its distribution partnership with Clariant, a global leader in the development and manufacturing of specialty chemical solutions. This expansion enhances LBBS's presence in Puerto Rico's robust Life Sciences sector, providing customers with local access to Clariant's pharmaceutical-grade excipients, including the VitiPure ™ product line. Under this expanded agreement, LBB Specialties will now support the Puerto Rico market with Clariant's full excipient portfolio, locally stocked inventory, and dedicated technical and commercial support on the island. This collaboration strengthens LBBS's ability to deliver high-purity, GMP-compliant excipients tailored for pharmaceutical and biopharmaceutical applications, including products designed for low endotoxin and tight microbial control. "Puerto Rico continues to be a preferred destination for companies establishing FDA-approved pharmaceutical manufacturing operations," said Seth Burns, Senior Vice President, Life Sciences at LBB Specialties. "By expanding our partnership with Clariant, we're reinforcing our commitment to supporting the region's Life Sciences ecosystem with best-in-class excipients and responsive local service. This expansion builds on our shared vision of advancing formulation innovation while ensuring supply chain reliability and technical excellence." "This expanded partnership with LBB Specialties represents a strategic advancement in our commitment to strengthening our global footprint," said Vaios Barlas, Head of Health Care at Clariant. "Local availability of our complete excipient portfolio directly addresses the needs of this important market. Clariant values LBBS's established presence and technical capabilities in Puerto Rico, which complement our focus on delivering pharmaceutical-grade ingredients that meet the highest quality and regulatory standards." For more information about Clariant's excipient solutions in Puerto Rico, please contact LBB Specialties today. About LBB Specialties LBB Specialties is a leader in North American specialty chemicals and ingredients distribution. It is a diversified supplier serving end markets including care, food & nutrition, industrial specialties, and life sciences. About Clariant Clariant is a focused specialty chemical company led by the overarching purpose of "Greater chemistry – between people and planet." By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On 31 December 2024, Clariant totaled a staff number of 10 465 and recorded sales of CHF 4.152 billion in the fiscal year for its continuing businesses. Since January 2023, the Group conducts its business through the three Business Units Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland. Clariant Health Care is a leading high-quality solution partner for the global pharmaceutical industry, with a strong portfolio of top-performing excipients and active pharmaceutical ingredients (APIs), backed by operational excellence and years of experience in regulatory affairs.
Cision Canada
4 days ago
- Cision Canada
Aktiia's Hilo Band Becomes First Cuffless Blood Pressure Monitor Cleared by FDA for Over-the-Counter Use
The FDA-cleared G0 Blood Pressure Monitoring System - marketed as Hilo Band - will bring cuffless blood pressure monitoring to U.S. consumers NEUCHTEL, Switzerland, July 9, 2025 /CNW/ -- Aktiia, a pioneer in optical blood pressure monitoring, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for over-the-counter (OTC) use of its cuffless blood pressure monitoring technology. This clearance, granted for Aktiia's G0 Blood Pressure Monitoring System, marks the first time the FDA has cleared a cuffless blood pressure monitor indicated for over-the-counter (OTC) use in the United States. While Aktiia's innovative blood pressure monitoring products are already CE marked and available in Europe under the brand Hilo, the product will be made available to US consumers in 2026. Trusted by over 130,000 users globally, the Hilo Band has demonstrated the impact of Aktiia's technology in real-world settings. With this FDA clearance, consumers in the U.S. will soon have access to the same clinically validated innovation behind the Hilo Band and app. With no medical prescription required, it is now the first cuffless blood pressure monitor authorized for over-the-counter use in the United States. The milestone sets a new global benchmark for how blood pressure can be effortlessly monitored through wearable, user-friendly technology. With this FDA clearance, Aktiia is now positioned to establish Hilo as the category-defining wearable for cuffless blood pressure monitoring in the U.S. and beyond. " This is not just a regulatory win: it's the start of a paradigm shift in hypertension management," said Josep Sola, Co-Founder and CTO of Aktiia. " With FDA's OTC clearance, we are breaking down the barriers that have kept cuffless blood pressure monitoring out of the hands of millions." " This milestone is the result of more than seven years of relentless scientific, clinical, and engineering effort," said Mattia Bertschi, Co-Founder of Aktiia. " What began as a research vision in the Swiss Research Institute CSEM twenty years ago has now become the world's first cuffless, FDA-cleared, over-the-counter solution for blood pressure – and we're just getting started." This regulatory clearance follows an oversubscribed Series B round of over $42 million USD co-led earlier this year by Earlybird Venture Capital and Wellington Partners. "Aktiia's FDA clearance represents a breakthrough moment for medical-grade wearables," said Dr. Christoph Massner, Principal at Earlybird and Board Director of Aktiia. "We backed the team because they combined bold vision with scientific rigor; and today they've delivered what no one else could. The Hilo Band is poised to lead a global transformation in how we understand and manage cardiovascular health at scale." The Hilo Band is not just another wearable: it is the first of its kind blood pressure companion, marking a breakthrough moment for cardiovascular health, much like the iPhone did for mobile technology. Due to its sleek, lightweight and comfortable form factor, the Hilo Band ushers in a new class of medical wearables that empower individuals to monitor their blood pressure anytime, anywhere. Achieving this milestone reinforces Aktiia's leadership in cuffless, consumer-ready blood pressure monitoring, redefining what's possible in everyday cardiovascular care. About Aktiia Founded in 2018, Aktiia is transforming the way blood pressure is measured and managed. By harnessing one of the world's largest datasets of optical signals, its cuffless monitoring product (commercially known as the Hilo Band) provides clinically meaningful insights to both individuals and healthcare professionals, making blood pressure tracking more accessible and effortless than ever before. With billions of optical signals and hundreds of millions of blood pressure readings collected from over 130,000 users, Aktiia has developed a robust and scalable solution to address one of the world's most pressing health challenges. Hypertension affects more than 1.3 billion people globally and remains the leading risk factor for cardiovascular disease; yet most cases remain undiagnosed or poorly managed. By enabling seamless and user-friendly monitoring at home, Aktiia is poised to transform how hypertension is detected and managed worldwide. Backed by a multidisciplinary team with deep expertise in biomedical signal processing and machine learning, Aktiia's innovation is supported by more than 120 peer-reviewed publications and over 35 patents. Headquartered in Switzerland, the company is expanding internationally to make accessible, cuffless blood pressure monitoring the new standard of care in home hypertension management. Note: The Hilo Band requires calibration using a cuff, which is provided with the purchase.
National Observer
4 days ago
- National Observer
Want to try lab-grown salmon? The US just approved it.
This story was originally published by Grist and appears here as part of the Climate Desk collaboration For the first time ever, a lab-grown seafood company has met the United States Food and Drug Administration's requirements for demonstrating the safety of a new cell-cultured product. Wildtype's cultivated salmon is now for sale in Portland, Oregon. This marks the first time that lab-grown seafood (also known as 'cultivated seafood' or 'cell-cultured seafood') is available for sale anywhere in the world, according to the Good Food Institute, a think tank that advocates for alternative proteins — substitutes for conventional meat made without relying on industrial animal agriculture. It's a major milestone for the emerging cultivated protein industry, which aims to deliver real meat and seafood at scale without replicating the environmental harms of large-scale livestock operations. It's also a sign that the Food and Drug Administration under the second Trump administration is allowing the regulatory process around lab-grown meat to continue without political interference, despite widespread Republican skepticism of the technology. Wildtype, which manufactures sushi-grade salmon by cultivating fish cells under laboratory conditions, is the fourth cultivated protein company to receive approval from the Food and Drug Administration, or FDA, to sell its product in the US. The company first reached out to the FDA to discuss the safety of its cultivated salmon during the first Trump administration in 2019, said co-founder and CEO Justin Kolbeck, adding that Wildtype underwent eight rounds of questioning from the agency over the next six years. Kolbeck described the experience as 'a science-driven, data-driven process' and said the team of regulators working with Wildtype stayed largely the same across the three presidential terms. 'Did it feel like a long time in the lifespan of an early-stage startup? Yes,' said Kolbeck. 'But it is completely appropriate, in my opinion. And the reason is that this is a new way to make food. And I think consumers have a right to feel like our food authorities turned over every stone that they can think of.' In a letter to the company, the FDA stated that it had 'no questions' about Wildtype's conclusion that its cell-cultivated salmon is 'as safe as comparable foods produced by other methods.' However, the agency did add that if Wildtype's manufacturing processes change, it should contact the FDA again for further consultation. The FDA did not respond to Grist's request for comment. The company is now partnering with Kann, a Haitian restaurant in Portland helmed by the James Beard Award-winning chef Gregory Gourdet. The restaurant began serving Wildtype's salmon weekly on Thursdays this month; in July, the fish will be on the menu full-time. Kolbeck said that Kann sold out of all its cultivated salmon portions on the first night of service. 'I don't think people saw this as some crazy, wild new thing,' he said. Instead, it was 'another option on the menu, which is ultimately what we're working for. We want to provide consumers with another option for seafood.' Consumers have an increasing number of choices for alternative proteins at grocery stores and restaurants — from plant-based burgers and chicken nuggets to faux meat made from fermented fungi. Like other alternative protein companies, cultivated protein brands often position their means of production as more sustainable than animal agriculture, the leading source of methane emissions in the US. But cultivated meat differs from other alternative proteins in that it's not vegan; it is meat, just without the mass animal slaughter. Even though federal regulators have approved only a handful of these products for sale, there has been growing political backlash to cultivated meat. Last month, three states with Republican-led legislatures enacted bills banning or temporarily banning the sale of such products: Nebraska, Montana, and Indiana. They join three other states with similar bans: Mississippi, where a law prohibiting cultivated meat sales unanimously passed in both the state House and Senate earlier this year; Alabama; and Florida. The governors of these states have framed these laws as necessary to protect consumers from 'fake meat' (as the Nebraska governor's office puts it) and ranchers from unfair competition in the marketplace. This posture casts doubt not just on the safety of cultivated foods, but also their legitimacy as meat. The Montana bill defines cultivated meat as 'the concept of meat … rather than from a whole slaughtered animal.' However, recent outcry from ranchers suggests these state officials do not speak for all agricultural producers and consumers; in Nebraska, for example, ranchers have welcomed competition from cultivated protein companies. Madeline Cohen, who heads the regulatory team at the Good Food Institute, argued these states are sacrificing a chance to create jobs and tax revenue. 'There are a small number of states that have chosen to put political wins over consumer choice and over our general free market system,' said Cohen. 'And they will now kind of be sitting on the sidelines, and they will miss out on economic opportunities.' But Kolbeck and other proponents argue that biotechnology is needed to meet the rising demand for meat and seafood without depleting the world's natural resources. Both overfishing — which happens when wild fish are harvested at a rate faster than they can reproduce — and warming temperatures pose risks to global food security. Research has shown that climate change has already impacted fish and shellfish populations around the world. Fish farms are an increasingly common alternative to wild fisheries, but these energy-intensive operations can pollute waterways. Kolbeck framed cultivated salmon as a way to reduce the food system's impact on aquatic ecosystems, protecting them for 'future generations so that people can continue to fish sustainably.' 'How do we take a little bit of pressure off of wild fish stocks and keep these places beautiful?' he said, referring to areas like Bristol Bay in Alaska, where the world's largest sockeye salmon fishery is located. Suzi Gerber, head of the Association for Meat, Poultry, and Seafood Innovation, or AMPS, a cultivated protein trade group, expressed optimism about the industry's future. She noted that Trump recently released an executive order calling to boost US seafood production. 'The timing is perfect,' said Gerber. 'Wildtype and other seafood producing members of AMPS are very happy to answer this call and to ensure a bright future for American seafood alongside our agricultural colleagues in aquaculture, wild, and farmed fisheries.' Eric Schulze, an independent consultant for cultivated meat companies and a former federal regulator, said that the FDA's thumbs-up to Wildtype should put Americans' mind at ease about cultivated meat. 'The US produces some of the safest food in the world — conventional and cultivated — and this clearance only elevates food safety and enhances consumer choice,' said Schulze. 'Everyone wins.'
